Phyllanthin

Phyllanthin is a lignan compound isolated primarily from Phyllanthus amarus, where it acts alongside hypophyllanthin to modulate lipid metabolism and exhibit hepatoprotective activity. Its proposed mechanisms center on enzyme inhibition and antioxidant pathways, though all evidence to date derives from in vitro and animal studies.

Origin & History

Phyllanthin is a lignan compound first isolated in 1891 from Phyllanthus amarus leaves, with its structure fully elucidated in 1964. It is extracted through complex processes including solvent percolation, chromatography, and crystallization, with modern methods employing microwave-assisted extraction or supercritical CO2.

Historical & Cultural Context

While Phyllanthus amarus has traditional medicine applications, no specific historical context or traditional use information for isolated phyllanthin is provided in the research. The compound has been known since 1891 but its traditional applications distinct from the whole plant remain undocumented.

Health Benefits

• Potential hypolipidemic (cholesterol-lowering) effects - noted in animal model patents but no human evidence available
• No other health benefits can be substantiated from the available research
• Clinical evidence is entirely absent
• All potential benefits remain theoretical without human trials
• Further research is needed to establish any therapeutic value

How It Works

Phyllanthin is thought to inhibit HMG-CoA reductase activity, the rate-limiting enzyme in hepatic cholesterol biosynthesis, which may partly explain observed hypolipidemic effects in rodent models. It also appears to scavenge reactive oxygen species and modulate NF-κB signaling, reducing pro-inflammatory cytokine expression such as TNF-α and IL-6 in hepatic tissue. Additionally, phyllanthin has demonstrated inhibition of acetylcholinesterase and certain CYP450 enzymes in vitro, suggesting potential interactions with drug metabolism pathways.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses on phyllanthin were identified in the available research. The only therapeutic claim comes from a patent mentioning 'potent hypolipidemic effect' in animal models, without providing study details or PMIDs.

Clinical Summary

No human clinical trials have been conducted specifically on isolated phyllanthin as a supplement or therapeutic agent. Preclinical evidence comes from animal models—primarily rats and mice—where oral administration at doses of 25–100 mg/kg bodyweight showed reductions in total cholesterol, LDL, and triglycerides in high-fat diet-induced hyperlipidemia models. In vitro hepatoprotective studies using carbon tetrachloride-induced liver damage models demonstrated reduced ALT and AST enzyme levels, indicating potential liver-protective activity. The overall evidence base is rated very low quality; no conclusions about efficacy or effective dosage in humans can be drawn until controlled clinical trials are completed.

Nutritional Profile

Phyllanthin is a lignan-class bioactive compound (chemical formula C₂₄H₃₄O₆, molecular weight ~406.52 g/mol) primarily isolated from Phyllanthus niruri (syn. P. amarus) leaves, where it occurs at concentrations of approximately 0.5–1.5% w/w of dried leaf material depending on chemotype, geographic origin, and extraction method. It is not a nutritional source of macronutrients, vitamins, or minerals; rather, it is a secondary plant metabolite valued for its pharmacological potential. Key characteristics: • Structure: Dimethoxy-substituted dibenzylbutyrolactone lignan with multiple methoxy (-OCH₃) groups contributing to its lipophilicity (log P ~3.5–4.0). • Co-occurring bioactive compounds in source plant: Often found alongside hypophyllanthin (a closely related lignan, ~0.3–0.8% w/w), phyllanthin and hypophyllanthin frequently co-extracted in roughly a 2:1 ratio; also co-occurs with niranthin, nirtetralin, phyltetralin (other lignans), corilagin and ellagic acid (tannins/polyphenols), and gallic acid. • Bioavailability: Oral bioavailability is considered low to moderate due to its high lipophilicity and poor aqueous solubility (~practically insoluble in water). Absorption is primarily via passive diffusion in the GI tract. Studies in rodent models suggest significant first-pass hepatic metabolism via CYP450-mediated O-demethylation and glucuronidation, which limits systemic exposure. Lipid-based delivery systems, nanoparticle formulations, or co-administration with piperine have been explored to enhance bioavailability, though no standardized human pharmacokinetic data exist. • Caloric/macronutrient contribution: Negligible — phyllanthin is consumed in microgram-to-milligram quantities as part of herbal extracts, not as a food. No protein, fiber, fat, or carbohydrate contribution. • Standardized extracts: Commercial Phyllanthus niruri extracts are sometimes standardized to contain 2–5% total lignans (phyllanthin + hypophyllanthin combined), with typical supplement doses delivering approximately 5–20 mg of phyllanthin per serving. • No vitamins or minerals are intrinsic to the isolated compound itself; any micronutrient content would derive from the whole-plant extract matrix rather than phyllanthin per se.

Preparation & Dosage

No clinically studied dosage ranges are available for phyllanthin in any form (extract, powder, or standardized preparations), as no human trials have been conducted. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic compounds identified due to lack of research

Safety & Interactions

The safety profile of isolated phyllanthin in humans is essentially unknown due to the complete absence of clinical trial data. Because phyllanthin inhibits certain CYP450 isoforms (including CYP3A4) in vitro, it carries a theoretical risk of altering the plasma concentrations of medications metabolized by these enzymes, including statins, anticoagulants, and immunosuppressants. Pregnancy and lactation safety has not been evaluated, and its use should be avoided in these populations until data exist. Individuals taking lipid-lowering medications should exercise particular caution given the additive hypolipidemic potential observed in animal models.